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Objective: To assess the consequences of different more or less selective treatments on the microbiological and 
inflammatory responses within the peritoneum. 
Methods: The early effects of various antibiotic regimens were evaluated in a model of polymicrobial peritonitis with 
specifically prepared organisms. Six regimens (amoxycillin plus gentamicin, pefloxacin, ornidazole, pefloxacin plus 
ornidazole, imipenem and imipenem plus gentamicin) were evaluated at 24 h and 3 days in  a non-fatal model of 
peritonitis in  rats achieved by implantation of a capsule containing fscherichia cob, Bacteroides fragilis and fntero- 
coccus faecalis. 
Results: Therapies that disregarded several organisms were associated with persistence of the strains and an increased 
peritoneal inflammatory response within the peritoneum. In contrast, therapies active against Enterobacteriaceae and 
anaerobes were associated with decreases of all the inoculated organisms and a smaller inflammatory response. 
Conclusion: Therapies that disregarded the microorganisms implicated in  peritoneal infection are associated with 
delayed bacterial eradication. The persistence of these organisms within the peritoneal fluid might be involved in  
prolonged peritoneal inflammation. Although it disregards enterococci, the standard therapy, represented by therapy 
against Enterobacteriaceae and anaerobes, demonstrates satisfactory effects towards all the inoculated organisms. This 
apparent contradiction could be related to  mechanisms of bacterial synergy. 
Key words: Peritonitis, antibiotic, cytokines, animal model, enterococci, anaerobes, empirical therapy, combination 
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INTRODUCTION 
Intra-abdominal infections are usually caused by a 
mixture of aerobic and anaerobic bacteria [l]. Experi- 
mental studies and clinical trials have demonstrated that 
antimicrobial therapy should provide adequate coverage 
for Gram-negative bacteria and anaerobes [2], while the 
need to treat enterococci is still being debated [2 ,3] .  
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The early effects of antibiotic therapy might play an 
important role in the outcome of the patients, as 
illustrated by two clinical studies which demonstrated 
that the prognosis was linked to a regimen active against 
all the peritoneal organisms from the beginning of 
therapy [4,5]. 
The use of an experimental model might provide 
a meaningful basis for the quantification of the effects 
of different types of antibiotic treatment and the 
additive effects of combinations of drugs, especially 
regarding mistreated organisms. However, most of the 
previous studies assessed the effects of therapy late in 
the course of infection [6-91 and used mortality or the 
presence of abscesses as final endpoints. 
We hypothesized that a focus on the early period 
of therapy would help in judging the relative efficacy 
of the antibiotic regimens and in assessing the effects of 
disregarded organisms on the host response. Therefore, 
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we used a rat model of polymicrobial peritonitis with 
specifically prepared strains in which we evaluated the 
early microbiological and inflammatory effects of 
targeted monospecific or polyspecific antimicrobial 
regimens. 
MATERIALS AND METHODS 
Organisms 
Three strains of bacteria previously described were used 
for this study [9]: an encapsulated strain of Bucteroides 
.fia<qilis, AIP5-86 (obtained from the collection of the 
Laboratoire des Anakrobies, Institut Pasteur, Paris, 
France); a strain of Eschevichia coli, CI31496; and a strain 
of Entevococcus fuecalir, UA174 (obtained from the 
collection of the Unit6 des Agents Anti-bactkriens, 
Institut Pasteur, Paris, France). The resistance of 
B. jagi1i.c to amoxycillin was due to penicillinase 
production. In the strain of Escherichiu coli, a plasmid 
pIP55 was inserted which encodes for the production 
of p-lactamase (Om-3 type) and for the production of 
an adenylyltransferase enzyme (AAD-2” type), leading 
to an isogenic strain resistant to amoxycillin and genta- 
micin. The strain of Enterococcus fuecalis had intrinsic 
low-level resistance to aminoglycosides. 
Animals 
One hundred and twelve male Sprague-Dawley 
pathogen-free rats (Charles River France, St-Aubin- 
les-Elbeuf, France), weighing 200-250 g, were used for 
all the experiments. Polymicrobial peritonitis was 
induced by the surgical implantation of a gelatin 
capsule previously described [9], using procedures in 
agreement with the European Regulation. I n  order 
to avoid the potential effects of sequential testing of 
different groups, we simultaneously tested four animals 
in each group. 
Preparation of the inoculum 
B. fragilis was grown anaerobically in prereduced 
thioglycolate broth, while Eschevichia coli and Entero- 
cocciis fuecalis were grown in brain-heart infusion broth. 
The three organisms were collected when they were in 
log phase of growth by centrifugation (1500 2 for 
10 niin). The pellets were then resuspended, diluted 
and mixed to obtain a final dilution of Eschevichia coli 
1 x lo8 CFU/mL + B. j u g i l i s  5 x lo7 CFU/mL + 
Entevococcus fueculir 1 x 10’ CFU/mL for the bacterial 
challenge. Semi-solid agar medium was prepared by 
adding 2%) (w/v) agar to the diluted broth cultures 
combined with barium sulfate (10% w/v). Aliquots 
(0.5 mL) of the final mixture were placed in double 
gelatin capsules for intraperitoneal implantation. 
Implantation of inoculum 
The animals were anesthetized with an intramuscular 
injection of ketamine (30 mg/kg body weight), and the 
gelatin capsule was inserted intraperitoneally into the 
pelvic cavity through a midline abdominal incision 
[lo]. The wound was closed with a musculoperitoneal 
layer and a skin layer using nylon sutures. After im- 
plantation of the inoculum, the animals were returned 
to separate cages. N o  death was observed within 6 h of 
capsule implantation. 
Antibiotic therapy 
Seven groups of 16 rats were studied, including a 
control group of 16 untreated animals. Six hours after 
inoculation, treated animals received intramuscularly 
one of the following regimens: amoxycillin (Smithkline 
Beecham, Nanterre, France) plus gentamicin (Labora- 
toires Schering-Plough, Levallois-Pezzet, France) given 
every 4 h (150 mg/kg and 8 mg/kg respectively): 
pefloxacin (Groupe RhBne-Poulenc Rorer, Montzouge, 
France) 65 mg/kg every 8 h; ornidazole (Produits 
Roche, Neuilly-sur-Seine, France) 125 mg/kg twice 
daily; pefloxacin 65 mg/kg every 8 h plus ornidazole 
125 mg/kg twice daily; imipenem-cilastatin (Labora- 
toire Merck Sharpe & Dohme-Chibret, Paris, France) 
17 mg/kg every 4 h; imipenem-cilastatin 17 mg/kg 
plus gentarnicin 8 mg/kg every 4 h. The doses of anti- 
biotics chosen for the investigation were based on the 
results of a previous study in which trough and peak 
concentrations of the drugs were assessed in plasma and 
peritoneal fluid [9], and were as close as possible to the 
concentrations obtained in humans. The MICs of every 
drug for aerobic and anaerobic strains were determined 
in a previous study 191. 
The antibiotic regimens were chosen to allow 
specific therapy for each organism. The combination 
of amoxycillin and gentamicin was active against 
Enterococcus faeculis, pefloxacin against Escherichia coli, 
ornidazole against B. frugilis ,  the combination of 
pefloxacin and ornidazole against Escherichia coli and 
B. j u g i l i s ,  and imipeneni against the three organisms. 
Increased killing of enterococci was expected with the 
addition of gentaniicin to imipeneni. 
Evaluation of treatment 
Microbiological parameters, peritoneal cellular responses 
and inflammatory cytokine responses, as described 
below, were used to evaluate bacterial interactions. 
In order to avoid any carryover effect, treatments 
were interrupted 4 h before sacrifice for amoxycillin, 
gentamicin and imipeneni, 8 h before sacrifice for 
pefloxacin, and 12 h before sacrifice for ornidazolc 191. 
In each group, eight animals were sacrificed 24 h and 
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3 days after bacterial challenge. Animals were killed 
with chloroform. 
Microbiological study 
Blood samples, obtained by aseptic percutaneous trans- 
thoracic cardiac puncture in all the animals, were used 
for blood cultures and measurements of cytokines. 
Then, 10 mL NaCl 0.9% was injected intra- 
peritoneally. A midline laparotomy was performed and 
peritoneal fluid samples were recovered from all regions 
of the peritoneal cavity. A dilution factor, taking into 
account the fluid present in the peritoneal cavity prior 
to the injection of serum saline, was applied in all 
calculations. We used urea as an endogenous marker 
of peritoneal dilution. Since urea diffuses readily 
throughout the body, the urea concentrations in 
peritoneal fluid and plasma are the same [l 11. In this 
setting, if the concentrations of urea in plasma and a 
lavage sample are known, the dilution of the initial 
volume of peritoneal fluid can be obtained as follows: 
Dilution factor = (concentration of urea in plasma)/ 
(concentration of urea in peritoneal fluid). Once the 
dilution factor is known, the concentration of any 
component in the peritoneal fluid (e.g. cytokines, cells 
or bacteria) can be assessed. The urea contents of 
peritoneal fluid and plasma were determined with a 
commercially available kit (Boehringer Mannheim, 
Meylan, France). 
A 0.5-mL aliquot of the peritoneal fluid sample 
was serially diluted, and 0.1 mL of each dilution was 
spread on agar plates for bacterial enumeration. The 
remaining peritoneal fluid was then centrifuged at low 
speed (300 g for 5 min), and cell-free supernatants were 
discarded. To determine the number of host-cell- 
associated viable bacteria, peritoneal cells pelleted by 
low-speed centrifugation were washed three times with 
phosphate-buffered saline (PBS) and incubated for 30 
min at 4OC with 0.1% Triton X-100 (Sigma Chemical 
Co., L'Isle d'Abeau, France). Serial dilutions were 
made, and 0.1 mL of each dilution was spread on agar 
for counting of intracellular bacteria and cell-related 
bacteria. These procedures did not alter the viability 
of bacteria. The reproducibility of the cell-pelleting 
technique was evaluated at the beginning of the 
investigation. Peritoneal samples were assayed in 
triplicate, and the standard deviation was 510% of the 
mean. 
The limit of detection for every microbiological 
test was 1 loglo CFU/mL. In cases of values below this 
threshold, the results were listed as 51 loglo. In the 
statistical analysis, these results were treated as 1 loglo. 
In every case, plates were incubated in the appropriate 
environments (i.e. jars or air) for 2-5 days. The selective 
medium used for detection of B. fragilis was Columbia 
agar base (BioMPrieux, Charbonni6res-les-Bains, 
France) with 5% sheep blood containing 75 mg 
kanamycin, 7.5 mg vancomycin and 4 mg pefloxacin 
per L. Selective media used for culture of aerobes were 
Drigalski agar (Diagnostics Pasteur, Marnes-la-Coquette, 
France) and bile-esculin-azide agar (Diagnostics Pasteur). 
No attempt was made to inactivate the anti- 
microbial agents in the materials, since the 1/1000 
dilution achieved before plating was shown to eliminate 
any carryover effect [9]. Antibiotic susceptibihty testing 
was done in the isolates cultured from peritoneal 
exudates and blood cultures. 
In vivo synergy of combination therapy was 
defined as a 1 loglo CFU/mL decrease in bacterial 
count compared to the count obtained with each of 
these regimens administered separately. 
Quantitation of host peritoneal leukocyte populations 
Total cell counts were obtained from an aliquot of the 
original peritoneal fluid using a Malassez counting 
chamber. Aliquots of original fluid, adjusted to 5 x lo4 
cells, were cytocentrihged using a Cytospin 2 (Shandon 
Inc., Pittsburgh, PA), and individual preparations from 
every rat were stained with May-Griinwald-Giemsa or 
Gram stains. Differential cell counts were obtained by 
examining at least 300 cells. The mean total number of 
intraperitoneal leukocytes as well as total macrophage 
(MC) and polymorphonuclear neutrophils (PMN) sub- 
populations were calculated and expressed as percentages 
of the total cell number. 
Cytokine assays 
Blood samples were drawn by cardiac puncture and 
placed into sterile glass tubes. After coagulation, the 
sera were divided into aliquots and kept a t  -70°C until 
assayed. Four 1-mL samples of the original peritoneal 
fluid recovered from all regions of the peritoneal cavity 
were centrifuged (300 g for 15 min) and then divided 
into aliquots and stored at -70OC until assayed. The 
serum and peritoneal samples were assayed in triplicate, 
and the standard deviation (SD) was 2 10% of the mean. 
The concentrations of tumour necrosis factor (TNF) 
were evaluated at 24 h, while the IL-6 concentrations 
were determined at 24 h and 3 days. 
TNF activity was determined with a cytotoxicity 
assay previously described [12]. The limit of detection 
in serum and peritoneal fluid was 0.12 ng/mL. The 
specificity of the response for TNF was assessed with 
an antimouse TNF antibody Ig fraction (Immugenex, 
Los Angeles, CA, USA). 
Interleukin-6 (IL-6) activity was measured by means 
of a bioassay, using the murine hybridoma cell line B9 
previously described [12]. The limit of detection in 
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serum and peritoneal fluid was 0.10 ng/mL. The 
specificity of the response for IL-6 was assessed using 
polyclonal rabbit antimurine IL-6 antibodies (Genzyme, 
Tebu SA, St-Quentin-en-Yvelines, France). 
Statistical analysis 
Results are expressed as means i SEM. The chi-square 
test or Fisher's exact test were used for the comparison 
of proportions. Analysis of variance, followed in case of 
significance by limited comparisons of means using 
Fisher's least significant difference procedure, was used 
for comparison between control untreated animals and 
treated animals and comparison between regimens. 
Statistical significance was inferred for comparisons for 
which P<O.Ol. 
Effects of treatments on survival 
All control animals survived. No mortality was 
observed in the treated groups prior to the end of the 
study. 
Effects of treatments on blood cultures 
At 24 h postinoculation, no significant change was 
observed between control and treated groups for the 
number of positive blood cultures (Table 1). At 3 days, 
the frequency of positive blood cultures remained 
unchanged in the control animals (Table 1). 
Effects of treatments on total peritoneal isolates 
The highest concentrations of pathogens were recorded 
at 24 h postinoculation, followed by a spontaneous 
decrease of the concentration of every organisni (Table 
2). In the animals receiving therapy for 24 h, decreased 
peritoneal counts of Eschevirhiu coli were observed in the 
two groups receiving pefloxacin (P<O.Ol when coni- 
pared to amoxycillin plus gentaniicin and ornidazole in 
both groups). The peritoneal counts of €3. frugilis were 
reduced in all the treated groups, but the largest 
decrease was observed in the animals that had been 
given ornidazole (ornidazole or pefloxacin plus 
ornidazole; P<O.OI when compared to the other 
regimens). A decrease was also noticed in peritoneal 
counts of Enterococc.ur faeculis with every treatment but 
Table 1 Number of aninids with positive blood culture5 at  the time of hacrifice after different therapeutic regimenu given 
for 24 h to 3 day\ 
24 h 3 d a y  
Escherichia Barleroidcs Ewrrococciv EAcherichio Bnctcroidcr Erlterocoecio 
Antimicrobial regimen ioli j q i l i s  .fieratis col1 fia'qili, faecali5 
8 8 8 8 
3 7 4 3 
Control untreated animals 8 8 
Pefloxacin 8 7 3 3 7 5 
Ornidazole 7 3 T) 3 ND" 2 '1 
I'efloxacin + ornidazole 8 7 4 ND,' I 3 
Anioxycillin + gcntainicin 8 7 
Imipenem 8 8 6 4 2 .I 3 
Imlpcnein + gentainicin 8 8 3 5 1 ,' 1" 
Eight animal5 were studied in each group. 
ND, not detected (<lo CFUIniL). 
"P<O.O1 when compared to control untreated animals. 
Table 2 Bacterial numbers within the peritoneal cavity at  the time of sacrifice 
24 h 3 d a y  
Eschrrichin Bacrrroides Eiirerucociirs Esrherichia Bnrtcror dcs 0 1  t r r o ~ o ~ i i ~ ~  
Antimicrobial regirneri ioli Jrngilis Joecalis culi jra<qiIis Jaecalis 
Control untreated animals 5.32 0.4 5.1 k0.2 4.6 * 0.1 3.8k0.4 3+0 7 3ri-0.2 
Pefloxacin 4.2k0. I" 3.710.2" 3.g i 0 . 1  a 2 6k0.2" 2 Sk(J.4 3.5+0.1 
Ornidazole 5.4k0.2 1.3f 0.1" 4.2kO.2 3.820.2 NIIa 3.2t 0.1 
l'eflouacin + ornidazole 4.2+0.12 2.310.1" 3.720.1 a 2.7 f 0.1 NI>" 2 4k0.2"  
Imipenem 4.620.2 3.7 k 0 3  3 t O . 2 ~  3.4k(i.l 1.250 1,' 220.2"  
Ainoxycillin + gentamcm 5.1 ?O.l 4.1kO.2" 3.7 I 0.1 4.2k0.2 3.750.4 2.3kO.l' 
Iniipenem + gentamicin 4.910.1 3 .h i0 . Ia  2.9k0.2" 3.450.2 1 . 5 1 0 . 2 ~  2. l iO.2" 
Results are presented as log l~  CFU/mL, mean + SEM; eight animals were studied in each group. 
ND. not detected ( < I 0  CFU/mL). 
.'P<O.Ol when compared to control untreated animals. 
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ornidazole. The most important decrease in entero- 
coccal counts was recorded in the two groups receiving 
imipenem (WO.01, when compared to the other 
groups in both cases). 
Decreased peritoneal counts of Escherichia coli and 
absence of detection of B. fragilis were reported in the 
animals receiving pefloxacin plus ornidazole for 3 days. 
Persistence of enterococci was observed in the animals 
receiving pefloxacin or ornidazole (W 0.01 versus 
other treated groups in both cases). Similarly, B. fragilis 
counts remained at the level of control untreated 
animals in the animals that had been given amoxycillin 
or pefloxacin ( P < O . O l  versus other regimens). Per- 
sistence of Escherichia coli was also noted in the animals 
treated with amoxycillin plus gentamicin ( P < O . O l  
versus other regimens). 
Effects of treatments on intracellular bacteria within the 
peritoneal cavity 
The highest concentrations of pathogens were recorded 
at 24 h postinoculation, followed by a spontaneous 
decrease in the concentration of every organism (Table 
3 ) .  In the animals treated for 24 h, the counts of 
Enterococcus faecalis were significantly decreased in the 
animals receiving the combination of imipenem and 
gentamicin (WO.01 versus other regimens except 
imipenem). 
In the animals treated for 3 days, the counts of 
B. fragilis remained unchanged in the animals that 
had been given amoxycillin and gentamicin (WO.01 
versus control group and versus every treated group). 
Similarly, persistently increased counts of enterococci 
were noted in the animals receiving pefloxacin or 
ornidazole (P<O.Ol versus control and versus every 
treated group in both cases). 
We did not observe any modification in the 
susceptibility pattern in any pathogens cultured after 
24 h or 3 days of treatment. The number of intracellular 
and cell-related bacteria within the peritoneal fluid 
closely followed the evolution of the total number of 
organisms in the peritoneal fluid. 
Effects of treatments on total leukocytes in the peritoneal 
cavity 
When compared to those of the untreated animals, 
leukocyte counts were significantly elevated after 24 h 
of therapy in the two groups of animals that had been 
given ornidazole (Figure 1). When compared to 24 h 
of treatment, a significant increase in the leukocyte 
counts was observed at 3 days in all the animals except 
I I 
H24 Day 3 
Figure 1 Leukocyte counts ( X lo6 cells/mL) (mean k SEM) 
collected at the time of sacrifice (24 h or 3 days) within the 
peritoneal cavity in untreated animals (O),  or animals 
receiving amoxycdhn plus gentamicin (+), pefloxacin (O), 
ornidazole ( A ) ,  pefloxacin plus ornidazole (W), imipenem 
(0) and imipenem plus gentamicin (0). 
*P<O.Ol when compared to control untreated animals. 
Table 3 Bacterial numbers of intracellular and cell-related bacteria within the peritoneal cavity at the time of sacrifice 
Antimcrobial regimen 
Control untreated animals 
Amoxycillin + gentamicin 
Pefloxacm 
Ornidazole 
Pefloxacm + ornidazole 
Imipenem 
Imipenem + gentamicin 
Escherichia 
coli 
4.7f0.4 
5.2f0.1 
3.9f0.2a 
5 . l fO. l  
4 f 0 . 1  
4.120.2 
4.7f0.1 
Bacteroides 
fragilis 
2.9f0.4 
2.5f0.1 
3.220.2 
ND a 
ND a 
1.6f0.3a 
1.7f0.2” 
Enteroroccus 
fuerulis 
3.4f0.2 
3.3f0.2 
3.2f0.1 
3.7f0.2 
3.5f0.1 
2.720.2 
2.1f0.3” 
Escherichia Bacteroides Enterococcus 
coli jiagiiis fueculis 
3.6f0.3 1.820.3 2.020.3 
4 .1 i0 .3  3.2f0.6” 2f0 .2  
2.3f0.2” 1.7f0.4 3.2f0.1” 
3.7k0.2 ND 2.9*0.1a 
2.3k0.2” ND 2 f  0.2 
2.9f0.2 1.1f0.1 1.6f 0.2 
3.2f0.2 ND 1.720.2 
Results are presented as loglo CFU/mL, meanf SEM; eight animals were studied in each group 
ND, not detected (< lo  CFU/mL). 
“P<0.01 when compared to control untreated animals. 
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in the two groups receiving ornidazole. Targeting all the groups, without any significant difference (data 
enterococci with amoxycillin plus gentamicin led to not shown). 
the highest late leukocyte recruitment, while targeting After 24 h of therapy, the concentrations of IL-6 
the two other organisms with pefloxacin plus ornidazole were significantly higher in the treated animals than in 
led to the lowest count. The percentage of PMN the control group (Figure 2B). However, no significant 
remained elevated for the 3 days of the study in all the difference was noted within treated animals. A signi- 
groups, without any difference within these groups ficant decline in the peritoneal concentration of IL-6 
(data not shown). was reported between 24 h and 3 days in the treated 
animals, except those receiving ornidazole (Figure 2B). 
Effects of treatments on cytokine release into the At 3 days, the concentrations of IL-6 remained 
circulation significantly increased in the groups that had been given 
The TNF concentrations measured in serum reached ornidazole or pefloxacin when compared to the control 
the limit of detection in all the groups treated for 24 group (Figure 2B). In addition, the concentrations of 
hours except for the animals receiving ornidazole and IL-6 in the ornidazole group were higher than those in 
imipenem plus gentamicin. No statistical difference was the other treated groups ( P < O . O l  when compared with 
noted between control and treated animals (data not every other group). 
I I 
shown). 
Although IL-6 was detected in serum, the 
concentrations observed were far below its peritoneal 
concentrations. Although IL-6 was measured in serum 
at  24 h in every group, we did not observe any 
significant difference between groups (Figure 2A). 
When compared to the animals treated for 24 h, the 
concentrations of IL-6 significantly decreased in the 
groups receiving pefloxacin plus ornidazole and 
amoxycillin plus gentamicin for 3 days (P<O.Ol in both 
cases) (Fig. 2A). In addition, the concentration of IL-6 
in the serum of animals treated with pefloxacin was 
lower than that in all the other treated animals (P<O.Ol 
in every case). 
Effects of treatments on cytokine release into peritoneum 
At 24 h, the concentrations of TNF within the 
peritoneal fluid reached the threshold of detection in 
DISCUSSION 
The need to treat all the organisnis isolated from the 
peritoneal fluid in the course of intra-abdominal 
infections is still being debated. Many different 
antibiotics, either singly or in combination, are active 
in vitro against the predominant species of bacteria 
found in intra-abdominal infections and might be 
expected to be effective for the treatment of these 
infections [2]. 
Since our goal was to focus on the disregarded 
organisms, we did not investigate all the therapeutic 
possibilities. In contrast with the spectrum of resistance 
of the inoculated organisms, which has some clinical 
relevance, the monospecific or polyspecific regimens 
presented herein do not represent standard care. These 
treatments were chosen to mimic the various thera- 
H24 Day 3 H24 Day 3 
Figure 2 Serum (A) and peritoneal (B) concentrations of IL-6 (ng/mL) (mean k SEM) at the time of sacrificc (24 h or 3 
days) in untreated animals (O),  or animals receiving amoxycillin plus gentamicin (+), pefloxacin (o), ornidazole ( A ) .  
pefloxacin plus ornidazole (w), imipenem (0) and imipenem plus gentamicin (0). 
*1-’<0.01 when compared to control untreated animals. 
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peutic possibilities encountered in the empirical treat- 
ment of intra-abdominal infections. In addition, we 
used a non-fatal model in order to closely evaluate the 
relationships between hosts and pathogens. 
Because of the design of the experimental plan, a 
spontaneous decrease in the numbers of the peritoneal 
pathogen was noted, as a consequence of phagocytosis 
and systemic diffusion of the organisms [12]. This is 
a very uncommon situation in clinical practice. 
Consequently, any extrapolation to the clinical setting 
would be hazardous. However, it must be noted that 
improvement or even cure of animals in models of 
cecal ligation-puncture receiving antibiotics is just as 
questionable, with just as limited clinical relevance. 
Several issues need to be considered in the 
interpretation of our results. The effects of antibiotics 
on peritoneal inflammation are not well known and 
might interfere with the local response to infection. 
Moreover, the inflammatory consequences of poly- 
microbial infection are not well known and the 
respective roles of each organism are difficult to 
determine. Although the effects of selective antibiotic 
therapy are difficult to assess in this setting, a focus on 
the early period of therapy is useful in judging the 
relative efficacy of the antibiotic regimens and in 
assessing the effects of disregarded organisms on the 
host response. 
In the present study, the high diffusibility of 
pefloxacin was emphasized by the remarkable decrease 
in the counts of Eschericliiu coli within blood and 
peritoneum in the two groups of animals receiving 
pefloxacin. By contrast, poor efficacy against this 
organism of imipenem was observed; this has been 
previously reported [9J and might be related to an 
inoculum effect and/or to a short half-life of the drug. 
The rapid efficacy of nitroimidazoles against B. 
frugilis has been previously reported in a model of 
subcutaneous abscess by Joiner et a1 [13]. These authors 
observed that these agents were the most efficient drugs 
in reducing the bacterial count of this organism. These 
results, as well as our study, suggest that nitroimidazole 
therapy for initial treatment of anaerobes in uncom- 
plicated intra-abdominal infection might be reduced to 
a short period of time. On the other hand, the 
synergistic effect of the combination pefloxacin- 
ornidazole against enterococci supports prolonged 
administration of both drugs. 
Some of the regimens commonly administered for 
intra-abdominal infections, such as third-generation 
cephalosporins, moxalactam or combinations of clinda- 
inycin and gentamicin, are only minimally active 
against enterococci [14]. Despite this apparent lack 
of activity, successful treatments of intra-abdominal 
infection have been reported with these drugs in 
experimental studies [6,7,15] and in clinical trials 
[ 16-1 81. In contrast, several clinical reports have 
mentioned the emergence of enterococcal abscesses 
and bacteremia in patients treated for intra-abdominal 
and biliary infections with antibiotic regimens that have 
little or no in vitro activity against enterococci [19-211. 
In contrast to enterococcal endocarditis, in which 
optimal therapy requires a synergistic combination of a 
cell wall-active agent and an aminoglycoside [22], the 
administration of amoxycillin plus aminoglycoside 
might be less than ideal in enterococcal intra- 
abdominal infections. In an enterococcal model of 
intra-abdominal abscess, Willey et a1 [8] demonstrated 
that the most effective regimen against this organism 
was a high daily dose of ampicillin. Our current results 
confirm previous observations [9], in which we reported 
a moderate efficacy of amoxycillin plus gentamicin 
against enterococci. In addition, the moderate benefit 
obtained by the addition of gentamicin to imipenem 
confirms the results of several clinical trials which 
demonstrated that aminoglycosides are not needed for 
initial treatment of uncomplicated intra-abdominal 
infections [2,23]. 
The effects of antibiotic therapy on the mech- 
anisms of bacterial synergy remain an unexplored field 
marked only by anecdotal reports. The antibiotic 
regimen used to treat intra-abdominal infection might 
influence the growth of enterococci present in the 
peritoneal fluid, even if they are outside of the 
spectrum of the antibiotics admmistered. Enterococcal 
emergence or superinfection were reported with the 
administration of third-generation cephalosporins, 
moxalactam [20,21], and fluoroquinolones [24]. A 
similar emergence of enterococci was reproduced by 
Dalhoff, in an experimental model of mixed infection, 
using cefotaxime [25]. The delayed decrease in the 
enterococcal counts observed in the current study after 
3 days in the animals that had been given pefloxacin or 
ornidazole might be related to similar mechanisms. In 
contrast, Willey et a1 mentioned that combinations of 
clindamycin or metronidazole and gentamicin exerted 
a suppressive effect against enterococci in a model of 
intra-abdominal abscess [8]. The mechanisms support- 
ing this suppressive effect remain unexplored but could 
be linked to bacterial synergy. Such results could 
explain the low frequency of enterococcal super- 
infection or persistent enterococci reported in clinical 
practice with these regimens. 
The inflammatory response is an additional way 
of assessing the effects of antibiotic therapy. Since 
peritoneal infection induces a compartmentalized 
response of the inflammatory cascade [12,26], the 
effects of antibiotic therapy need to be considered, 
especially in cases of mixed infection. This point is of 
7 0 8  Cl in ica l  M i c r o b i o l o g y  a n d  I n f e c t i o n ,  V o l u m e  4 N u m b e r  1 2 ,  D e c e m b e r  1998 
interest, especially because the inflammatory response 
in the peritoneuni can be enhanced by Gram-positive 
cocci [12]. In addition, the potential effects of serum 
proteins must be taken into account, since they might 
inactivate endotoxin before its proinflammatory activity 
can be expressed, a point usually disregarded in the 
vitro studies. 
With the regimens applied, we did not observe 
any enhancement of the T N F  response within the 
peritoneal fluid, but investigation of this mediator at 
24 h is late in the course of the inflammatory response 
[12]. By contrast, an increased concentration of IL-6 in 
the peritoneal fluid was reported with all therapeutic 
regimens at 24 h when compared to control animals. 
This issue is of interest since previous experimental 
studies demonstrated that the inflammatory response 
following exposure to carbapenems, or quinolones was 
moderate when compared to the effects obtained with 
p-lactam antibiotics [27,28]. 
An increased cellular count within the peritoneum 
was noted in the group that had been given amoxycillin 
plus gentamicin. In this situation, the role of untreated 
Enterobacteriaceae and anaerobes cannot be excluded. 
Similarly, the persistence of enterococci or anaerobes 
might influence the inflammatory response. The in- 
creased concentrations of IL-6 within the peritoneal 
fluid of the animals treated with pefloxacin or ornidazole 
might be linked to such a mechanism. Bhakdi et a1 [29] 
demonstrated the ability of lipoteichoic acid from 
enterococci to stimulate production of IL-I@, IL-6 and 
TNF-a by cultured monocytes. 
In view of our results, we conclude that therapies 
which disregard any particular microorganism implicated 
in peritoneal infection are associated with a delay in 
the bacterial eradication of this microorganism. The 
persistence of these organisms within the peritoneal 
fluid might be involved in prolonged peritoneal 
inflammation or even in the emergence of secondary 
abscesses. However, these issues remain to be assessed. 
Although it disregards enterococci, the standard 
therapy represented by treatment against Enterobac- 
teriaceae and anaerobes demonstrates satisfactory effects 
on all the inoculated organisms. This apparent con- 
tradiction could in fact be related to several mechanisms, 
such as bacterial synergism and bactericidal activity of 
the drugs administered, and could explain the good 
results of these regimens reported in clinical practice 
over the last 20 years. 
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